Optimal Treatment for Patients with Oligometastatic Prostate Cancer

Urologia Internationalis - Tập 106 Số 3 - Trang 217-226 - 2022
Bülent Çetin1, Chiara A. Wabl2, Özge Gümüşay2
1Division of Medical Oncology, Department of Internal Medicine, Suleyman Demirel University Faculty of Medicine, Isparta, Turkey
2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Tóm tắt

Oligometastatic prostate cancer (PCa) can be defined as cancer with a limited number of metastases, typically fewer than 5 lesions, and involves lesions contained within the axial versus the appendicular skeleton. Patients can present with de novo oligometastatic, oligorecurrent, or oligoprogressive PCa. Oligometastatic PCa patients demonstrate considerable improvements in survival outcomes, with a better prognosis than patients with extensive metastatic disease. However, the management of patients that present with nonsymptomatic oligometastatic PCa remains difficult. In the oligometastatic setting, the benefit of local therapies such as prostatectomy and radiotherapy on survival outcomes is an intriguing topic; however, their impact on oncological outcomes is still unknown.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21442

10.1016/j.euf.2017.10.014

10.1200/jco.1995.13.1.8

10.1038/nrclinonc.2011.44

10.1002/1097-0142(19880101)61:1%3c195::aid-cncr2820610133%3e3.0.co;2-y

10.1016/j.eururo.2015.07.004

10.1016/j.eururo.2014.07.020

10.1002/pros.23645

10.1016/j.radonc.2016.07.021

10.1016/j.juro.2012.06.046

10.1056/NEJMoa1503747

10.1056/NEJMoa1704174

10.1200/JCO.2017.75.4853

10.1001/jamaoncol.2020.0147

10.1016/j.eururo.2018.06.004

10.1016/S0140-6736(18)32487-5

10.1016/j.eururo.2018.10.041

10.1016/j.eururo.2013.11.012

10.1200/JCO.2016.67.4788

10.1016/S0140-6736(18)32486-3

10.1016/j.eururo.2019.02.003

10.1016/j.eururo.2020.01.012

10.1016/j.juro.2014.09.089

10.1016/j.euf.2017.06.016

10.1016/j.eururo.2015.05.023

10.1016/j.juro.2018.08.050

10.1002/pros.21259

10.1002/cncr.20243

10.1038/sj.onc.1210843

10.1016/j.eururo.2012.03.050

10.1016/S1470-2045(10)70223-0

10.1200/JCO.2017.75.3657

10.1016/j.eururo.2020.01.012

10.1016/S1470-2045(19)30082-8

10.1056/NEJMoa1702900

10.1093/annonc/mdz396

10.1016/j.eururo.2019.08.006

10.1200/JCO.19.00799

10.1056/NEJMoa1903307

Thông tin
Thông tin xuất bản

Urologia Internationalis

Tập 106 Số 3

217-226

Thông tin tác giả